Diabetic Retinopathy Market Size, Growth, Trends, Report 2024-2033
The global diabetic retinopathy market was surpassed at USD 9.55 billion in 2023 and is expected to hit around USD 17.88 billion by 2033, growing at a CAGR of 6.47% from 2024 to 2033.
Diabetic retinopathy, a complication arising from diabetes, holds a prominent position in the healthcare landscape due to its widespread prevalence and impact on visual health. This overview aims to provide insights into the key facets of the diabetic retinopathy market, encompassing its current status, growth drivers, challenges, and notable trends.
The growth of the diabetic retinopathy market is propelled by several key factors. Firstly, the increasing prevalence of diabetes worldwide, particularly the rising incidence of type 2 diabetes, contributes significantly to the expanding patient pool at risk of diabetic retinopathy. Advances in diagnostic technologies, such as retinal imaging and artificial intelligence-driven solutions, facilitate early detection, fostering improved patient outcomes. Additionally, ongoing research and development initiatives focused on innovative treatment modalities and therapies contribute to the market's growth, providing healthcare professionals with more effective tools to manage diabetic retinopathy. The collaborative efforts of pharmaceutical companies, medical device manufacturers, and research institutions further drive advancements, ensuring a dynamic landscape that addresses the evolving needs of individuals affected by diabetic retinopathy. Overall, the interplay of these factors positions the diabetic retinopathy market for continued expansion and innovation in the quest for enhanced patient care and vision preservation.
| Report Coverage | Details |
| Market Revenue by 2033 | USD 17.88 billion |
| Growth Rate from 2024 to 2033 | CAGR of 6.47% |
| Revenue Share of North America in 2023 | 38% |
| CAGR of Asia Pacific from 2023 to 2032 | 7.08% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
The non-proliferative diabetic retinopathy (NPDR) category held the largest revenue share of 71% in 2023. This dominance is attributed to the growing aging population and an increase in blindness cases related to diabetes. NPDR, also known as background retinopathy, is a prevalent diabetic eye condition and a significant cause of blindness in adults. Typically advancing from mild to moderate stages, NPDR is characterized by microaneurysms, small blood-filled bulges in artery walls, which can leak into the retina. While NPDR itself may not pose a direct threat to vision, it can progress to diabetic macular edema, causing swelling in the macula and resultant vision loss. As the severity of NPDR grows, so does the risk of developing vision-threatening proliferative diabetic retinopathy.
On the other hand, the proliferative diabetic retinopathy (PDR) segment is anticipated to experience a highest CAGR during the forecast period. PDR represents an advanced stage of retinopathy where delicate blood vessels proliferate inside the retina and vitreous humor, leading to blurred vision and, ultimately, blindness. Macular edema may develop without early symptoms, requiring comprehensive eye examinations for diagnosis, such as visual acuity tests and tonometry. Laser surgery is a common treatment method for PDR, facilitating the shrinkage of blood vessels.
Anti-VEGF drugs had the largest market share of 93% in 2023, owing to their effectiveness in treating diabetic retinopathy. These drugs, widely utilized for addressing proliferative diabetic retinopathy (PDR), demonstrate notable efficacy, particularly in cases involving vitreous hemorrhage, neovascular glaucoma, and procedures preceding vitrectomy. Administered via injection into the eye, anti-VEGF agents impede the formation of fragile blood vessels, effectively slowing down the progression of retinopathy. The current market offers four major anti-VEGF agents—Eylea, Avastin, Lucentis, and Macugen—all of which received U.S. FDA approval in 2011 for treating Diabetic Macular Edema (DME).
In contrast, intraocular steroidal injections are emerging as a novel treatment for diabetic macular edema (DME) and diabetic retinopathy, gradually gaining traction in the market compared to anti-VEGF agents. These injections contain corticosteroid-based drugs that regulate cellular proliferation. Triamcinolone (Durezol) stands out among the examined corticosteroids, exhibiting superior therapeutic performance and establishing a robust market presence. Additional segments in retinopathy management include laser surgery and vitrectomy. The projected rise in proliferative diabetic retinopathy cases is anticipated to propel the market for intraocular steroidal injections in the forecast period.
North America dominated the market with the largest market share of 38% in 2023. This dominance is attributed to the region's advanced healthcare infrastructure, supportive government initiatives in drug development, and high levels of awareness among both patients and practitioners. The market's substantial share is further propelled by the widespread adoption of innovative products like anti-VEGF drugs—Lucentis, Avastin, and Eylea. Major drivers include robust healthcare expenditure, increased awareness of diabetes among the population, well-established healthcare facilities, and a favorable reimbursement framework.
Asia Pacific region is expected to expand at the highest CAGR of 7.08% during the forecast period. This growth is particularly driven by China and Japan, with China leading the diabetic retinopathy industry in the region in terms of revenue share. Factors contributing to this growth include the presence of major market players, a rising prevalence of diabetes, technological advancements in diabetic retinopathy treatments, an increasing geriatric population, and a growing incidence of lifestyle diseases, such as obesity.
In June 2023 Eyenuk has received FDA clearance for its Topcon NW400 retinal camera with its EyeArt AI system for the autonomous AI detection of diabetic retinopathy.
In January 2023, Eyenuk has received European Union Medical Device Regulation (MDR) certification for its EyeArt AI eye screening system. This certification covers the detection of diabetic retinopathy, age-related macular degeneration, and glaucoma.
By Type
By Management
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Diabetic Retinopathy Market
5.1. COVID-19 Landscape: Diabetic Retinopathy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Diabetic Retinopathy Market, By Type
8.1. Diabetic Retinopathy Market, by Type, 2024-2033
8.1.1. Proliferative Diabetic Retinopathy
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Non-proliferative Diabetic Retinopathy
8.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Diabetic Retinopathy Market, By Management
9.1. Diabetic Retinopathy Market, by Management, 2024-2033
9.1.1. Anti-VEGF
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Intraocular Steroid Injection
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Laser Surgery
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Vitrectomy
9.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Diabetic Retinopathy Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Type (2021-2033)
10.1.2. Market Revenue and Forecast, by Management (2021-2033)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Type (2021-2033)
10.1.3.2. Market Revenue and Forecast, by Management (2021-2033)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Type (2021-2033)
10.1.4.2. Market Revenue and Forecast, by Management (2021-2033)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Type (2021-2033)
10.2.2. Market Revenue and Forecast, by Management (2021-2033)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Type (2021-2033)
10.2.3.2. Market Revenue and Forecast, by Management (2021-2033)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Type (2021-2033)
10.2.4.2. Market Revenue and Forecast, by Management (2021-2033)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Type (2021-2033)
10.2.5.2. Market Revenue and Forecast, by Management (2021-2033)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Type (2021-2033)
10.2.6.2. Market Revenue and Forecast, by Management (2021-2033)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Type (2021-2033)
10.3.2. Market Revenue and Forecast, by Management (2021-2033)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Type (2021-2033)
10.3.3.2. Market Revenue and Forecast, by Management (2021-2033)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Type (2021-2033)
10.3.4.2. Market Revenue and Forecast, by Management (2021-2033)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Type (2021-2033)
10.3.5.2. Market Revenue and Forecast, by Management (2021-2033)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Type (2021-2033)
10.3.6.2. Market Revenue and Forecast, by Management (2021-2033)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Type (2021-2033)
10.4.2. Market Revenue and Forecast, by Management (2021-2033)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Type (2021-2033)
10.4.3.2. Market Revenue and Forecast, by Management (2021-2033)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Type (2021-2033)
10.4.4.2. Market Revenue and Forecast, by Management (2021-2033)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Type (2021-2033)
10.4.5.2. Market Revenue and Forecast, by Management (2021-2033)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Type (2021-2033)
10.4.6.2. Market Revenue and Forecast, by Management (2021-2033)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Type (2021-2033)
10.5.2. Market Revenue and Forecast, by Management (2021-2033)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Type (2021-2033)
10.5.3.2. Market Revenue and Forecast, by Management (2021-2033)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Type (2021-2033)
10.5.4.2. Market Revenue and Forecast, by Management (2021-2033)
Chapter 11. Company Profiles
11.1. Bayer AG
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. ABBVIE INC.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Novartis AG
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Oxurion NV
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. Sirnaomics
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Alimera Sciences
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Ampio Pharmaceuticals Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. BCNPeptides
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Kowa Company Ltd.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Genentech, Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers